Minaris Advanced Therapies

Overview

Minaris Advanced Therapies, established in 1999 and based in the United States, operates within the Business Services sector, specifically focusing on research and development in the field of cell and gene therapies. With a workforce of 501 to 1,000 employees, the company is engaged in addressing the complexities associated with biologic therapeutics. Their published documents highlight significant themes such as the evaluation of rapid testing methods for mycoplasma contamination in cell and gene therapy products, emphasizing the importance of safety, purity, and efficacy in biopharmaceutical manufacturing. For instance, one white paper discusses the challenges posed by traditional mycoplasma testing methods, which require large sample volumes and extended turnaround times, and introduces advanced technologies like bioMérieux’s BIOFIRE® for quicker detection. Additionally, a technical report outlines strategies to reduce cost barriers in scalable adeno-associated virus (AAV) manufacturing, indicating Minaris's commitment to enhancing the efficiency and accessibility of advanced therapeutic solutions. Overall, Minaris Advanced Therapies is positioned as a key player in the evolving landscape of biologic research and development.

Industry